As the chemotherapy based on 5-FU, Irinotecan, Oxaliplatin etc. remains for almost a decade as the most effective current anti-CRC therapy, these clinical findings suggest that low CBX3 expression may favor the efficacy of chemotherapy in CRC patients. The gene discussed is CBX3; the disease is colorectal carcinoma.